IMB-401 / IMBiologics - LARVOL DELTA

State-of-the-art Specific T cell Activating Modulator on ePENDY platform (STAM.eP) activates specific CD8+ T cell by stimulating TCR signal (AACR 2024) - "Furthermore, we confirmed that IMB-401 shows anti-tumor efficacy due to an increase of antigen-specific CD8+ T cell in vivo humanized mouse model. These results suggest that IMB-401 can be a new therapeutic cancer vaccine technology that replaces DC function and is expected to have robust anti-tumor activity in combination with immune checkpoint inhibitors."

Cervical Cancer • Head and Neck Cancer • Oncology • Solid Tumor • CD8

IM Bio, attracts 4 billion seeds.. “OX40L-TNFα antibody rate“ (Google translation) (Biospectator) - "A new bio-venture, IMBiologics, announced on the 19th that it has completed attracting 4 billion won of seed investment. KB Investment and Atinum Investment participated in this investment...IMBIO plans to speed up the research and development of the...immune anti-cancer antibody pipeline (IMB-401) based on its own platform technology."

Financing • Oncology